Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors

PaperCitations, authors & open-access status

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 236 citations, 2017 year and closed oa status.

236
Citations
2017
Year
closed
OA Status

Related on ScholarIQ

Rebecca Kristeleit
Author
Amit M. Oza
Author
Clinical Cancer Research
Journal
PARP inhibition in cancer therapy
Topic
PARP inhibition in cancer therapy
Topic
BRCA gene mutations in cancer
Topic
470M+ articles · free account